HIV-2 CRF01-AB: First circulating recombinant form of HIV-2

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 3, 2010, Pages 241-247

  Ibe, Shiro ^a   Yokomaku, Yoshiyuki ^a   Shiino, Teiichiro ^b   Tanaka, Rie ^c   Hattori, Junko ^a   Fujisaki, Seiichiro ^a   Iwatani, Yasumasa ^a,d   Mamiya, Naoto ^a   Utsumi, Makoto ^a   Kato, Shingo ^c   Hamaguchi, Motohiro ^a   Sugiura, Wataru ^a,b,d  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

circulating recombinant form; CRF01 AB; HIV 2; molecular epidemiology

Indexed keywords

ENVELOPE PROTEIN; GAG PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COTE D'IVOIRE; FEMALE; GENE STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; MALE; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PRIORITY JOURNAL; VIRUS GENOME; VIRUS RECOMBINANT;

ADULT; BASE SEQUENCE; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HIV INFECTIONS; HIV-2; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; JAPAN; MALE; MOLECULAR EPIDEMIOLOGY; MOLECULAR SEQUENCE DATA; PHYLOGENY; REASSORTANT VIRUSES; VIRAL LOAD;

EID: 77954088791     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181dc98c1     Document Type: Article

References (47)

1. Marlink R. Lessons from the second AIDS virus HIV-2. AIDS. 1996; 10: 689-699.
2. Schim van der Loeff MF, Aaby P. Towards a better understanding of the epidemiology of HIV-2. AIDS. 1999;13:S69-S84.
3. Bock PJ, Markovitz DM. Infection with HIV-2. AIDS. 2001;15:S35-S45.
4. de Silva TI, Cotten M, Rowland-Jones SL. HIV-2: the forgotten AIDS virus. Trends Microbiol. 2008;16:588-595.
5. Whittle H, Morris J, Todd J, et al. HIV-2-infected patients survive longer than HIV-1-infected patients. AIDS. 1994;8:1617-1620.
6. Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science. 1994;265: 1587-1590.
7. Kanki PJ, Travers KU, MBoup S, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet. 1994;343:943-946.
8. Adjorlolo-Johnson G, De Cock KM, Ekpini E, et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA. 1994;272:462-466.
9. Ota MO, O'Donovan D, Alabi AS, et al. Maternal HIV-1 and HIV-2 infection and child survival in The Gambia. AIDS. 2000;14:435-439.
10. O'Donovan D, Ariyoshi K, Milligan P, et al. Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia. MRC/Gambia Government/University College London Medical School working group on mother-child transmission of HIV. AIDS. 2000;14:441-448.
11. Schim van der Loeff MF, Jaffar S, Aveika AA, et al. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia. AIDS. 2002;16:1775-1783.
12. SM-related HIV-2 in West Africa. Nature. 1992;358:495-499.
13. Gao F, Yue L, Robertson DL, et al. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol. 1994;68:7433-7447.
14. Chen Z, Luckay A, Sodora DL, et al. Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys. J Virol. 1997;71:3953-3960.
15. Yamaguchi J, Devare SG, Brennan CA. Identification of a new HIV-2 subtype based on phylogenetic analysis of full-length genomic sequence. AIDS Res Hum Retroviruses. 2000;16:925-930.
16. Damond F, Worobey M, Campa P, et al. Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification. AIDS Res Hum Retroviruses. 2004;20:666-672.
17. Ndembi N, Abraha A, Pilch H, et al. Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaoundé, Cameroon: evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B. J Clin Microbiol. 2008;46:177-184.
18. Yamaguchi J, Vallari A, Ndembi N, et al. HIV type 2 intergroup recombinant identified in Cameroon. AIDS Res Hum Retroviruses. 2008; 24:86-91.
19. Robertson DL, Hahn BH, Sharp PM. Recombination in AIDS viruses. J Mol Evol. 1995;40:249-259.
20. Kusagawa S, Imamura Y, Yasuoka A, et al. Identification of HIV type 2 subtype B transmission in East Asia. AIDS Res Hum Retroviruses. 2003; 19:1045-1049.
21. Utsumi T, Nagakawa H, Uenishi R, et al. An HIV-2-infected Japanese man who was a long-term nonprogressor for 36 years. AIDS. 2007;21: 1834-1835.
22. Kato S, Hanabusa H, Kaneko S, et al. Complete removal of HIV-1 RNA and proviral DNA from semen by the swim-up method: assisted reproduction technique using spermatozoa free from HIV-1. AIDS. 2006; 20:967-973.
23. Kinai E, Hanabusa H, Kato S. Prediction of the efficacy of antiviral therapy for hepatitis C virus infection by an ultrasensitive RT-PCR assay. J Med Virol. 2007;79:1113-1119.
24. Damond F, Loussert-Ajaka I, Apetrei C, et al. Highly sensitive method for amplification of human immunodeficiency virus type 2 DNA. J Clin Microbiol. 1998;36:809-811.
25. Tamura K, Dudley J, Nei M, et al. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol. 2007;24: 1596-1599.
26. Lole KS, Bollinger RC, Paranjape RS, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol. 1999;73: 152-160.
27. Drummond AJ, Rambaut A. BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol. 2007;7:214.
28. Drummond AJ, Ho SY, Phillips MJ, et al. Relaxed phylogenetics and dating with confidence. PLoS Biol. 2006;4:e88.
29. Wilgenbusch JC, Swofford D. Inferring evolutionary trees with PAUP*. Curr Protoc Bioinformatics. 2003;Chapter 6:Unit 6.4.
30. Rodŕguez F, Oliver JL, Maŕn A, et al. The general stochastic model of nucleotide substitution. J Theor Biol. 1990;142:485-501.
31. Lemey P, Pybus OG, Wang B, et al. Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci USA. 2003;100:6588-6592.
32. Pybus OG, Drummond AJ, Nakano T, et al. The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach. Mol Biol Evol. 2003;20:381-387.
33. Robertson DL, Anderson JP, Bradac JA, et al. HIV-1 nomenclature proposal. In: Kuiken CL, Foley B, Hahn B, et al, eds. Human Retroviruses and AIDS 1999. Los Alamos, NM: Los Alamos National Laboratory; 1999:492-505.
34. Robertson DL, Anderson JP, Bradac JA, et al. HIV-1 nomenclature proposal. Science. 2000;288:55-56.
35. Calef C, Mokili J, O'Connor DH, et al. Numbering positions in SIV relative to SIVMM239. In: Kuiken C, Foley B, Hahn B, et al, eds. HIV Sequence Compendium 2001. Los Alamos, NM: Los Alamos National Laboratory; 2001:171-181.
36. Lin G, Bertolotti-Ciarlet A, Haggarty B, et al. Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists. J Virol. 2007;81: 9956-9966.
37. Wertheim JO, Worobey M. Dating the age of the SIV lineages that gave rise to HIV-1 and HIV-2. PLoS Comput Biol. 2009;5:e1000377.
38. Pieniazek D, Ellenberger D, Janini LM, et al. Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast. AIDS Res Hum Retroviruses. 1999;15:603-608.
39. Zeh C, Pieniazek D, Agwale SM, et al. Nigerian HIV type 2 subtype A and B from heterotypic HIV type 1 and HIV type 2 or monotypic HIV type 2 infections. AIDS Res Hum Retroviruses. 2005;21:17-27.
40. Hessol NA, Koblin BA, van Griensven GJ, et al. Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1991. Am J Epidemiol. 1994;139:1077-1087.
41. Veugelers PJ, Page KA, Tindall B, et al. Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study. Am J Epidemiol. 1994;140:747-758
42. UK Register of HIV Seroconverters Steering Committee. The AIDS incubation period in the UK estimated from a national register of HIV seroconverters. AIDS. 1998;12:659-667.
43. Pezzotti P, Galai N, Vlahov D, et al. Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: results from the ALIVE and ISS studies. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:275-282
44. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet. 2000;355:1131-1137.
45. Morgan D, Mahe C, Mayanja B, et al. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS. 2002;16:597-603.
46. Poulsen AG, Aaby P, Larsen O, et al. 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa. Lancet. 1997;349:911-914.
47. Berry N, Jaffar S, Schim van der Loeff M, et al. Low level viremia and high CD4% predict normal survival in a cohort of HIV type-2-infected villagers. AIDS Res Hum Retroviruses. 2002;18:1167-1173.